VivoSeq
Cardiovascular

Cerebral Aneurysm

2

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Cerebral Aneurysm is an early-stage landscape with 2 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Sinomed Neurovita Technology Inc..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

PreclinicalM

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

PreclinicalS

Sinomed Neurovita Technology Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

A Prospective, Multi-center, Single Arm Clinical Study to Evaluate the Safety and Effectiveness of the Flow Diverter Stent System in the Treatment of Cerebral Aneurysms
Completed·SSinomed Neurovita Technology Inc.·Preclinical·NCT05774782·143 enrolled
Effects of Remifentanil Versus Esmolol on Optic Nerve Sheath Diameter/Eyeball Transverse Diameter Ratio During Endotracheal Intubation in Patients Undergoing Cerebral Aneurysm Coil Embolization: A Randomized Controlled Trial
Not yet recruiting·FFatih Sultan Mehmet Training and Research Hospital·Preclinical·NCT07660861·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)